A mounting body of evidence has demonstrated a potential link between metabolic disorders (such as type 2 diabetes, obesity and atherosclerosis) and chronic low‐grade inflammation characterized by abnormal cytokine or lipid mediator production and the activation of a network of inflammatory signalling pathways in tissues targeted by insulin, including fat, liver and muscles 27. This evidence concerns the gene INS and type 2 diabetes mellitus.